Introduction: Asthma is one of the most prevalent chronic medical conditions to complicate pregnancy. Similarly, active management strategies that prioritise asthma control in this vulnerable population can have a far-reaching impact. Results: Forty-two pregnant asthmatics were included, with a median age (interquartile range)of 32 (27-34) years; all had a previous medical diagnosis of asthma and rhinitis, 76% were atopic, 94% sensitised to dust mites and 43% were polissensitised. More than 80% presented poor control (CARAT (T) < 24) in the first assessment and 15% had a percentage forced expiratory volume in the first second < 80%. There were significant negative correlations between CARAT (L) and CARAT (T) scores and step-up of controller medication, (correlation coefficients = −0.453 and −0.392, respectively).
(IUGR), preterm delivery and preeclampsia. 5, 6 Moreover, asthma exacerbations are associated with an increased risk of any congenital malformation. 7 On the other hand, when properly controlled, asthma is associated with a favourable fetal and maternal prognosis and well-controlled asthma is fundamental for an uncomplicated pregnancy and a healthy newborn. 3 A subjective assessment of asthma control has little benefit in the discrimination of controlled and uncontrolled patients and this may lead to insufficient treatment or excessive use of medication.
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In pregnant women, shortness of breath is the most common respiratory complaint. Nonetheless, this is not associated with other typical asthma symptoms such as wheezing, chest tightness and cough. 9 Thus, asthma control evaluation in pregnant asthmatics, may be a challenge for clinicians because of the many physiological peculiarities associated with the pregnancy itself.
According to the Global Initiative for Asthma (GINA), control is based on asthma symptoms, limitation on daily life activities, nocturnal symptoms/awakenings, exacerbations with the need of rescue medication and lung function tests (forced expiratory volume in the first second (FEV1)).
10
In order to achieve and maintain asthma control in pregnancy, regular assessment and appropriate treatment of asthma and concomitant diseases that can affect the control is necessary.
Allergic rhinitis (AR) is frequently associated with asthma and its control. According to the Allergic Rhinitis and its Impact on Asthma (ARIA) recommendations, the management of these two conditions must be held jointly. 11, 12 However, the tools available to objectively evaluate AR control are scarce.
The Control of Allergic Rhinitis and Asthma Test (CARAT) is the only validated self-administered questionnaire that evaluates asthma and AR control concurrently and it was developed in Portugal. 13 The first study that assessed the association between the results of the CARAT questionnaire and spirometry parameters, performed in adults with asthma and/or AR, demonstrated a weak correlation between CARAT scores and percentage of predicted FEV1 (%FEV1). 14 To our knowledge, no study has evaluated the association of CARAT scores and spirometry in pregnant asthmatics.
The primary aim of this study was to describe the lung function parameters and the results of the CARAT questionnaire in a series of pregnant women with asthma and/or AR. As a secondary objective, we sought to analyse possible associations between CARAT scores and spirometric data during pregnancy.
MATERIALS AND METHODS
This was a longitudinal study, including pregnant women with asthma and AR followed in an Allergy and Clinical
Immunology Department. 
Study population
All pregnant women who underwent spirometry during the study period were included. Those with only one lung function assessment were excluded (Fig. 1) . 
RESULTS
Forty-two pregnant women were included (Fig. 1) , all with a previous medical diagnosis of asthma and rhinitis. The median age (IQR) was 32 (27-34) years. All were non-smokers. Thirty-two (76%) were atopic, 30 (94%) sensitised to dust mites, 16 (50%) to pollens, 9 (28%) cat and/or dog dander and 18 (43%) were polysensitised ( Table 1) .
At the first observation, 10 (24%) were obese (BMI > 30).
Fourteen (33%) did not have any controller medication for asthma and rhinitis, 27 (64%) used inhaled corticosteroids, six (14%) used topical nasal steroids and 31 (74%) were medicated with antihistamines for exacerbations (Table 1) .
Of the 14 women without controller medication, 64% reported that they were not on any medication because of fear of harm to the fetus and 36% were advised to interrupt their medication by the doctor who was monitoring the pregnancy.
In the first evaluation, almost 15% of the pregnant patients had %FEV1 < 80% and approximately 30% had an abnormal spirometry.
In these, almost 17% presented moderate obstruction and none had severe obstruction or mixed/restrictive ventilatory defects.
The spirometry classification, performed throughout the different assessments during the pregnancy remained constant (Table 2) .
At the first visit, the assessment of the upper airway symptoms using CARAT (U) score showed poor control in 74% and the scores of the lower respiratory tract symptoms according to CARAT (L) also showed poor control in 71%. A significant improvement in the 
DISCUSSION
The goal of asthma treatment in pregnant women is to achieve control in order to prevent exacerbations, maintain maternal health and optimise fetal growth. Treatment should be adjusted to the lowest dose to maintain control.
Despite the importance of adequate treatment 16 and its safety, there is still interruption of treatment by pregnant women or by However, published studies so far have not been conclusive as to the impact of treatment. There may be a connection between controlling GERD to aid in asthma control but high-quality research to prove this is lacking. More robust research is required to establish or remove this link. 10 Moreover, in this sample, acid reflux symptoms were not associated with asthma exacerbations and the need for step-up of asthma medication.
Allergic rhinitis is frequently associated with asthma and it may require the use of topical nasal corticosteroids and/or antihistamines. In this study, only 14% of the pregnant women were medicated with nasal corticosteroids but 74% resorted to antihistamines.
Asthma in pregnancy should be monitored more regularly and this should include lung function evaluation, as recommended by the guidelines. 3 In this sample, the mean %FEV1 throughout the evaluations remained above 80%. However, in the first evaluation, nearly 30% of the pregnant women had ventilatory obstructive defects, but none with severe obstruction or mixed/restrictive changes. This distribution of obstructive changes remained constant throughout the different assessments.
In relation to CARAT (T), there was poor control in the first evaluation in almost 81% of the pregnant women, as well as CARAT (U) in 74% and CARAT (L) in 71% of the patients.
There was a significant improvement in control for the three scores throughout the different assessments. These results may be related to better adherence to treatment and closer medical supervision.
No significant correlation was found between CARAT scores and %FEV1. This correlation was weak in previous studies with CARAT 14 and other asthma control questionnaires. 17, 18 This may be explained by the sample size.
However, significant negative correlations were detected between the CARAT (T) and CARAT (L) scores and the need for stepping up controller medication.
In our opinion, these results support the combined use of CARAT and lung function tests in the clinical assessment of asthma during pregnancy, for closer monitoring and the evaluation of any necessary treatment adjustments. Step up medication -4 (9,5) - 
CONCLUSION
The joint use of tools such as spirometry and validated questionnaires, particularly the CARAT, to objectively assess asthma control during pregnancy should be applied on a regular basis.
The data presented in this study reinforces the importance of close monitoring of pregnant asthmatics in order to achieve and maintain control of the disease.
